Barinthus Bio Q1 loss widens to $19.6M; CFO Brown out, CEO Enright takes PFO; presents Phase 2 HBV data

Barinthus Biotherapeutics plc.

2025-Q1 EPS reported -$0.49

Net loss $19.6M ($0.49/share) vs $15.5M ($0.40) in Q1 2024; R&D spending down to $8.3M from $11.1M.
Cash $100.6M as of Mar 31, down from $112.4M; company expects runway into 2027.
CFO Gemma Brown terminated Apr 30 in restructuring; CEO William Enright named principal financial officer, Brown stays as principal accounting officer until successor.
HBV003 trial: 33% (15/45) of low baseline HBsAg participants achieved ≥1 log decline; 71% met NUC discontinuation criteria; no SAEs.
IM-PROVE II: 25% (2/8) of participants with baseline HBsAg <1000 IU/mL reached functional cure; all seroconverted.

item 2.02 item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Gemma Brown

principal accounting officer

BRNS · Barinthus Biotherapeutics plc.

Effective: 2025-05-01
Filed: May 7, 2025, 7:59 PM ET

and Ms. Brown as principal accounting officer

Appointed

William Enright

principal financial officer

BRNS · Barinthus Biotherapeutics plc.

Effective: 2025-05-01
Filed: May 7, 2025, 7:59 PM ET

appointed William Enright, the Company’s Chief Executive Officer, as principal financial officer

Departed

Gemma Brown

Chief Financial Officer

BRNS · Barinthus Biotherapeutics plc.

Effective: 2025-04-30
Filed: May 7, 2025, 7:59 PM ET

Effective as of April 30, 2025, the Company terminated the employment of Gemma Brown as Chief Financial Officer in connection with its restructuring plan that was announced in 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gemma Brown was appointed as principal accounting officer at Barinthus Biotherapeutics plc..

Action: appointed
Role: principal accounting officer

Exact text from the filing

and Ms. Brown as principal accounting officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

William Enright was appointed as principal financial officer at Barinthus Biotherapeutics plc..

Action: appointed
Role: principal financial officer

Exact text from the filing

appointed William Enright, the Company’s Chief Executive Officer, as principal financial officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Gemma Brown was terminated as Chief Financial Officer at Barinthus Biotherapeutics plc..

Action: terminated
Role: Chief Financial Officer

Exact text from the filing

Effective as of April 30, 2025, the Company terminated the employment of Gemma Brown as Chief Financial Officer in connection with its restructuring plan that was announced in 2025.

View on SEC.gov

Barinthus Biotherapeutics plc. filing history →

Source: SEC EDGAR

accession 0001828185-25-000036

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.